8-K: Prestige Consumer Healthcare Exceeds Q2 Expectations, Raises FY26 EPS Outlook

Prestige Consumer Healthcare Inc. reported Q2 FY26 results surpassing sales and earnings forecasts, driven by supply timing and retailer orders, and updated its full-year adjusted EPS outlook to the high end of its previous range.

Summary

• Prestige Consumer Healthcare Inc. announced financial results for the second fiscal quarter and first six months ended September 30, 2025.
• Second quarter revenues were $274.1 million, a 3.4% decrease from $283.8 million in the prior year, primarily due to limited Clear Eyes supply.
• Q2 diluted EPS was $0.86, down from $1.09 in the prior year, while non-GAAP adjusted diluted EPS was $1.07, compared to $1.09 in the prior year.
• First six months revenues totaled $523.6 million, a 5.0% decrease from $550.9 million in the prior year, also impacted by Clear Eyes supply constraints and Q4 prior year accelerated orders.
• First six months diluted EPS was $1.81, down from $2.06 in the prior year, but non-GAAP adjusted diluted EPS increased to $2.02 from $1.98.
• Net cash provided by operating activities for the first six months of fiscal 2026 was $136.5 million, up from $124.6 million in the prior year.
• Non-GAAP free cash flow for the first six months was $133.6 million, an increase from $121.4 million in the prior year.
• The company repurchased approximately 1.1 million shares for $75.0 million in Q2 FY26, and 1.6 million shares for $109.8 million in 1H FY26.
• Net debt as of September 30, 2025, was approximately $0.9 billion, with a covenant-defined leverage ratio of 2.4x.
• The company reaffirmed its fiscal 2026 net sales outlook of $1,100 million to $1,115 million and organic revenue growth decrease of approximately 1.5% to 3.0%.
• The fiscal 2026 adjusted diluted EPS outlook was updated to the higher end of the previous range, now $4.54 to $4.58.
• Fiscal 2026 free cash flow outlook was reaffirmed at $245 million or more.

Sentiment

Score: 7

Explanation: The company exceeded Q2 sales and earnings expectations, increased 1H free cash flow by 10%, and raised its full-year adjusted EPS outlook to the high end of the range. While revenue declined due to Clear Eyes supply constraints, management is actively addressing this with anticipated improvements in the second half and the Pillar5 acquisition. Share repurchases demonstrate confidence and capital allocation discipline.

Positives

• Q2 FY26 revenue of $274.1 million and earnings surpassed internal sales and earnings expectations.
• Non-GAAP adjusted diluted EPS for the first six months of fiscal 2026 increased to $2.02, up 2.0% over the prior year comparable period.
• Non-GAAP free cash flow for the first six months of fiscal 2026 was $133.6 million, a 10% increase over the prior year comparable period.
• The company opportunistically repurchased approximately 1.1 million shares for $75.0 million in Q2 FY26, demonstrating disciplined capital allocation.
• The company's net debt position of approximately $0.9 billion and covenant-defined leverage ratio of 2.4x provide capital allocation optionality.
• International OTC Healthcare segment revenues for the first six months increased approximately 3% excluding the effects of foreign currency.
• eCommerce sales continue to benefit from long-term investments, showing double-digit consumption growth.
• The company's investment in the dental guards category has led to over 50% market share for its DenTek brand.
• The fiscal 2026 adjusted diluted EPS outlook was updated to the higher end of the previous range, now $4.54 to $4.58.
• The fiscal 2026 free cash flow outlook was reaffirmed at $245 million or more.

Negatives

• Reported revenues in Q2 FY26 decreased 3.4% to $274.1 million from $283.8 million in Q2 FY25.
• Reported revenues for the first six months of FY26 decreased 5.0% to $523.6 million from $550.9 million in 1H FY25.
• The revenue decline was primarily driven by lower Ear & Eye Care category sales due to limited ability to supply demand for Clear Eyes.
• Q2 FY26 diluted EPS of $0.86 and adjusted diluted EPS of $1.07 decreased compared to $1.09 in the prior year comparable period.
• Reported net income for Q2 FY26 totaled $42.2 million, down from $54.4 million in Q2 FY25.
• Reported net income for 1H FY26 totaled $89.7 million, down from $103.4 million in 1H FY25.
• Non-GAAP EBITDA for Q2 FY26 decreased 5.5% to $86.8 million from $91.9 million in Q2 FY25.
• Non-GAAP EBITDA for 1H FY26 decreased 3.0% to $166.5 million from $171.5 million in 1H FY25.
• North American OTC Healthcare segment revenues decreased in both Q2 and 1H FY26, primarily due to Clear Eyes supply issues.

Risks

• Impact of business and economic conditions, including evolving U.S. and international tariffs and trade actions, labor shortages, inflation, and geopolitical instability.
• Consumer trends and their impact on product demand.
• Effectiveness of the company's advertising, marketing, and new product development initiatives.
• Customer inventory management initiatives.
• Fluctuating foreign exchange rates impacting international revenues and costs.
• Competitive pressures within the consumer healthcare market.
• Ability to meet closing conditions for the Pillar5 acquisition.
• Ability to rapidly increase the supply of Clear Eyes from Pillar5 and other suppliers.
• Ability of the company's manufacturing operations and third-party manufacturers, logistics providers, and suppliers to meet demand for its products and to avoid inflationary cost increases and supply disruption.
• Ability to pass along rising costs to customers without negatively impacting sales.

Future Outlook

The company reaffirms its fiscal 2026 net sales outlook of $1,100 million to $1,115 million, anticipating eye care supply improvements in the second half due to long-term capacity efforts. The Adjusted Diluted EPS outlook is updated to the higher end of the previous range, now $4.54 to $4.58, and free cash flow is expected to be $245 million or more. The Pillar5 transaction is expected to close in Q3 FY26.

Management Comments

• Ron Lombardi, CEO: "Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes supply timing and the timing of certain retailer orders."
• Ron Lombardi, CEO: "We remain pleased with the performance of the remainder of our business, where we continue to focus on brand-building behind our diverse portfolio of leading brands and maintaining our leading financial profile."
• Ron Lombardi, CEO: "This proven formula continues to generate robust free cash flow, which enabled us to repurchase over one million in shares during the second quarter to further enhance shareholder value."
• Ron Lombardi, CEO: "For the full-year, we remain committed to rebuilding long-term supply chain capacity in Clear Eyes and expect to close the Pillar5 transaction as planned."
• Ron Lombardi, CEO: "For profitability, we are now expecting earnings per share at the higher end of our previous range as well as free cash flow of $245 million or more, driven by our strong financial profile and share repurchases executed in the second quarter."
• Ron Lombardi, CEO: "We continue to remain focused on long-term brand-building that drives long-term organic growth, alongside disciplined capital allocation that helps generate superior shareholder value creation over time."

Industry Context

The company is actively investing in the attractive dental guards category, where its DenTek brand has achieved over 50% market share, fueling category growth through high-impact omnichannel activations and culturally relevant storytelling. Additionally, eCommerce sales are experiencing double-digit consumption growth, benefiting from the company's long-term investments in digital channels.

Stakeholder Impact

• Shareholders: Potential for enhanced value through opportunistic share repurchases, increased free cash flow, and a raised full-year adjusted EPS outlook. The company's focus on long-term organic growth and disciplined capital allocation aims for superior shareholder value creation.
• Customers: Anticipated improvements in Clear Eyes supply in the second half of the fiscal year should lead to better product availability.
• Suppliers: Continued reliance on third-party manufacturers and logistics providers, with ongoing efforts to meet product demand and manage inflationary cost increases.

Next Steps

• Rebuilding long-term supply chain capacity for Clear Eyes products.
• Closing the Pillar5 transaction as planned in Q3 FY26.
• Continuing brand-building efforts behind its diverse portfolio of leading brands.
• Maintaining disciplined capital allocation to generate shareholder value.
• Conducting investor presentations using the provided slides throughout the fiscal year ended March 31, 2026.

Key Dates

Recommendation

While Prestige Consumer Healthcare exceeded Q2 sales and earnings expectations and raised its full-year adjusted EPS outlook, the reported revenue for both the quarter and first half declined primarily due to supply constraints for its Clear Eyes product. The company's strong free cash flow, opportunistic share repurchases, and commitment to addressing supply chain issues and brand-building are positive indicators. However, until the Clear Eyes supply fully normalizes and organic revenue growth consistently returns, a 'hold' recommendation is appropriate. The stock appears to be managing challenges effectively, but significant upside may be limited until the revenue growth trajectory is clearer.

Keywords

Prestige Consumer Healthcare, PBH, Q2 earnings, fiscal 2026, financial results, consumer healthcare, OTC, Clear Eyes, Pillar5, share repurchase, free cash flow, EPS, revenue, debt, leverage, DenTek, Dental Guards